Orforglipron vs VIP
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronImmune SupportSleep Optimization
VIP- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
- Half-Life
- ~12 hours (once-daily oral dosing)
- ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
- Admin Route
- Oral
- Intranasal, SubQ, IV
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 50 mcg (4 sprays of 12.5 mcg each)
- Frequency
- Once daily
- 4x daily
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Potent anti-inflammatory for CIRS and mold illness
- Improves pulmonary hypertension symptoms
- Regulates gut motility and IBS symptoms
- Modulates circadian rhythm and sleep quality
- Reduces mast cell activation (MCAS)
- Improves cognitive function in neuroinflammatory conditions
- Vasodilatory — reduces vascular resistance
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Facial flushing (transient, intranasal)
- Mild nausea
- Headache at initiation
- Hypotension at high doses
- +1 more
- Stacks With
- —
- —